what company makes retatrutide 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide Shows 28% Weight Loss

doi: 10.1016/j.soard.2018.03.003

To view or add a comment, sign in For the past few months, I've been watching the Medicare GLP-1 Bridge Program develop, and here's what strikes me most about it: CMS is finally admitting something the provider networks in Southern Nevada have known for years

The injectable GLP-1 medications currently on the market have published higher average weight loss figures in their landmark trials: Semaglutide (Wegovy): Demonstrated approximately 14.9% average body weight reduction in the STEP 1 trial

Why GLP-1s Are Revolutionary: Historical Context: Before GLP-1 medications: Weight loss medications produced 3-7% average weight loss Only bariatric surgery achieved 15-30% weight loss Many people couldnt access surgery due to cost, risk, or preferences Gap existed between ineffective pills and invasive surgery GLP-1s filled this gap: Producing 10-22% weight loss with medication alone Non-surgical option with bariatric-level results Relatively few contraindications Once-weekly administration Generally well-tolerated How GLP-1 Medications Work: Natural Hormone Mimicry: GLP-1 is a hormone your body naturally produces in your intestines after eating

Try This Week Today: Add an extra serving of broccoli or spinach to dinner

Now, the latest studies from healthcare and science professionals are exploring their potential beyond weight loss support alone